American Association for Cancer Research

Annual Meeting 2012 Program: Methods Workshops

Sessions as of February 15

Methods Workshops

Clinical Research: From Biology to Changing Standards of Care
Chairperson: Maha H. Hussain, University of Michigan Medical School, Ann Arbor, MI

  • Richard B. Gaynor, Eli Lilly and Company, Indianapolis, IN
  • Stephen L. George, Duke University Medical Center, Durham, NC
  • Maha H. Hussain
  • Anthony J. Murgo, FDA-CDER, Silver Spring, MD

Engineering T-Cell Therapy for Antitumor Effects in Humans
Chairperson: Helen E. Heslop, Baylor College of Medicine, Houston, TX

  • Laurence Cooper, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Mark E. Dudley, National Cancer Institute, Bethesda, MD
  • Helen E. Heslop
  • Richard J. O'Reilly, Memorial Sloan-Kettering Cancer Center, New York, NY

Genome-Wide Association Studies
Chairperson: Christopher A. Haiman, Zilkha Neurogenetic Institute, Los Angeles, CA

  • David Conti, University of Southern California, Los Angeles, CA
  • David J. Duggan, Translational Genomics Research Institute, Phoenix, AZ
  • Matthew L. Freedman, Dana-Farber Cancer Institute, Boston, MA
  • Kenneth Offit, Memorial Sloan-Kettering Cancer Center, New York, NY

Measuring DNA Repair Status in the Clinic: Biomarker Analyses and Incorporation Into Clinical Trials
Chairperson: Robert G. Bristow, University of Toronto, Princess Margaret Hospital (UHN), Toronto, ON, Canada

  • Robert G. Bristow
  • Thomas Helleday, Oxford University, Oxford, United Kingdom
  • Laura J. Niedernhofer, University of Pittsburgh, Pittsburgh, PA
  • Simon N. Powell, Memorial Sloan-Kettering Cancer Center, New York, NY

Modeling Pediatric Malignancy
Chairperson: A. Thomas Look, Dana-Farber Cancer Institute, Boston, MA

  • W. Brent Derry, The Hospital for Sick Children, Toronto, ON, Canada
  • Charles Keller, Oregon Health and Science University, Portland, OR
  • David M. Langenau, Massachusetts General Hospital, Charlestown, MA
  • A. Thomas Look

Molecular Imaging
Chairperson: E.G. Elisabeth De Vries, University Medical Center Groningen, Groningen, The Netherlands

  • Samuel Achilefu, Washington University School of Medicine, St. Louis, MO
  • E.G. Elisabeth De Vries
  • Go M. Van Dam, University Medical Center Groningen, Groningen, The Netherlands
  • Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA

Next-Generation Sequencing: Issues Moving Into the Clinical Arena
Chairperson: Katherine L. Nathanson, University of Pennsylvania School of Medicine, Philadelphia, PA

  • Leslie G. Biesecker, National Institutes of Health, Bethesda, MD
  • Gail Jarvik, University of Washington, Seattle, WA
  • Katherine L. Nathanson
  • Victor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Omics Approach to Adaptive Clinical Trials
Chairperson: Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Donald A. Berry
  • Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
  • Joe W. Gray, OHSU Knight Cancer Institute, Portland, OR
  • Laura J. van 't Veer, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Phase II Trials: Are We Asking Too Much?
Chairperson: Elizabeth S. Garrett-Mayer, Medical University of South Carolina Hollings Cancer Center, Charleston, SC

  • Gary M. Clark, Array Biopharma, Inc., Boulder, CO
  • Elizabeth S. Garrett-Mayer
  • Susan G. Hilsenbeck, Baylor College of Medicine Cancer Center, Houston, TX
  • Charles M. Rudin, Johns Hopkins University, Baltimore, MD

“Seqing" the Future of Cancer
Chairperson: X. Shirley Liu, Dana-Farber Cancer Institute, Boston, MA

  • Gordon L. Hager, National Cancer Institute, Bethesda, MD
  • W. Lee Kraus, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
  • X. Shirley Liu
  • Ting Wang, Washington University School of Medicine, St. Louis, MO

Target Identification for Drugs and Bioactive Small Molecules
Chairperson: Shao-En Ong, University of Washington, Seattle, WA

  • Sheng Ding, University of California, San Francisco, CA
  • Jing Huang, University of California Los Angeles Pharmacology, Los Angeles, CA
  • Shao-En Ong
  • Markus Schirle, Novartis Institutes for BioMedical Research Inc., Cambridge, MA


View other Annual Meeting 2012 sessions